These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31989894)

  • 21. The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease.
    Evens AM; Kostakoglu L
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):135-43. PubMed ID: 25696846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 18F-FDG PET/CT for Prognostic Stratification of Patients With Extranodal Natural Killer/T-Cell Lymphoma.
    Qin C; Yang S; Sun X; Xia X; Li C; Lan X
    Clin Nucl Med; 2019 Mar; 44(3):201-208. PubMed ID: 30624268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Prognostic value of 18F-FDG PET-CT in Hodgkin lymphoma].
    Ying Z; Wang X; Song Y; Zheng W; Wang X; Xie Y; Lin N; Tu M; Ping L; Liu W; Deng L; Zhang C; Yang Z; Zhu J
    Zhonghua Xue Ye Xue Za Zhi; 2014 Apr; 35(4):325-7. PubMed ID: 24759021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT.
    Mikhaeel NG; Timothy AR; O'Doherty MJ; Hain S; Maisey MN
    Leuk Lymphoma; 2000 Nov; 39(5-6):543-53. PubMed ID: 11342337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concomitant semi-quantitative and visual analysis improves the predictive value on treatment outcome of interim 18F-fluorodeoxyglucose/positron-emission tomography in advanced Hodgkin lymphoma.
    Biggi A; Bergesio F; Chauvie S; Bianchi A; Menga M; Fallanca F; Hutchings M; Gregianin M; Meignan M; Gallamini A
    Q J Nucl Med Mol Imaging; 2021 Dec; 65(4):410-415. PubMed ID: 28750493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FDG PET in response evaluation of bulky masses in paediatric Hodgkin's lymphoma (HL) patients enrolled in the Italian AIEOP-LH2004 trial.
    Lopci E; Mascarin M; Piccardo A; Castello A; Elia C; Guerra L; Borsatti E; Sala A; Todesco A; Zucchetta P; Farruggia P; Cistaro A; Buffardi S; Bertolini P; Bianchi M; Moleti ML; Bunkheila F; Indolfi P; Fagioli F; Garaventa A; Burnelli R;
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):97-106. PubMed ID: 30219963
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prognostic value of 18F-FDG PET-CT in the management of Hodgkin's lymphoma: preliminary results of a prospective study.
    Paolini R; Rampin L; Rodella E; Ramazzina E; Banti E; Al-Nahhas A; Rubello D
    Nucl Med Rev Cent East Eur; 2007; 10(2):87-90. PubMed ID: 18228212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Poor predictive value of positive interim FDG-PET/CT in primary mediastinal large B-cell lymphoma.
    Lazarovici J; Terroir M; Arfi-Rouche J; Michot JM; Mussot S; Florea V; Ghigna MR; Dartigues P; Petrovanu C; Danu A; Fermé C; Ribrag V; Ghez D
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2018-2024. PubMed ID: 28634685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.
    Press OW; Li H; Schöder H; Straus DJ; Moskowitz CH; LeBlanc M; Rimsza LM; Bartlett NL; Evens AM; Mittra ES; LaCasce AS; Sweetenham JW; Barr PM; Fanale MA; Knopp MV; Noy A; Hsi ED; Cook JR; Lechowicz MJ; Gascoyne RD; Leonard JP; Kahl BS; Cheson BD; Fisher RI; Friedberg JW
    J Clin Oncol; 2016 Jun; 34(17):2020-7. PubMed ID: 27069074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Automated quantification of reference levels in liver and mediastinal blood pool for the Deauville therapy response classification using FDG-PET/CT in Hodgkin and non-Hodgkin lymphomas.
    Sadik M; Lind E; Polymeri E; Enqvist O; Ulén J; Trägårdh E
    Clin Physiol Funct Imaging; 2019 Jan; 39(1):78-84. PubMed ID: 30284376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Different predictive values of interim
    Kim J; Lee JO; Paik JH; Lee WW; Kim SE; Song YS
    Ann Nucl Med; 2017 Jan; 31(1):1-11. PubMed ID: 27627889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy.
    Simontacchi G; Filippi AR; Ciammella P; Buglione M; Saieva C; Magrini SM; Livi L; Iotti C; Botto B; Vaggelli L; Re A; Merli F; Ricardi U
    Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1077-1083. PubMed ID: 26031367
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Dercle L; Seban RD; Lazarovici J; Schwartz LH; Houot R; Ammari S; Danu A; Edeline V; Marabelle A; Ribrag V; Michot JM
    J Nucl Med; 2018 Jan; 59(1):15-24. PubMed ID: 28596157
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of FDG PET-CT in the treatment management of Hodgkin lymphoma.
    Berriolo-Riedinger A; Becker S; Casasnovas O; Vander Borght T; Édeline V
    Cancer Radiother; 2018 Sep; 22(5):393-400. PubMed ID: 30033076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hodgkin lymphoma: Response assessment by revised International Workshop Criteria.
    Brepoels L; Stroobants S; De Wever W; Spaepen K; Vandenberghe P; Thomas J; Uyttebroeck A; Mortelmans L; De Wolf-Peeters C; Verhoef G
    Leuk Lymphoma; 2007 Aug; 48(8):1539-47. PubMed ID: 17701585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Paediatric and adolescent Hodgkin lymphoma: information derived from diffuse organ uptake of 18 F-fluorodeoxyglucose on pre-treatment and on interim PET/CT.
    Jorgov L; Montravers F; Balogova S; Ragu C; Pacquement H; Leblanc T; Abbou S; Ducou-Lepointe H; Landman-Parker J; Talbot JN
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1220-30. PubMed ID: 26660144
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
    Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF
    Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Can Interim 18F-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy?: A Preliminary Study in 15 Patients.
    Mayerhoefer ME; Karanikas G; Kletter K; Kiesewetter B; Weber M; Rausch I; Pones M; Simonitsch-Klupp I; Müllauer L; Dolak W; Lukas J; Raderer M
    Clin Nucl Med; 2016 Nov; 41(11):837-843. PubMed ID: 27648705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation.
    Mesguich C; Cazeau AL; Bouabdallah K; Soubeyran P; Guyot M; Milpied N; Bordenave L; Hindié E
    Br J Haematol; 2016 Nov; 175(4):652-660. PubMed ID: 27539369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early interim FDG PET/CT prediction of treatment response and prognosis in pediatric Hodgkin disease-added value of low-dose CT.
    Ilivitzki A; Radan L; Ben-Arush M; Israel O; Ben-Barak A
    Pediatr Radiol; 2013 Jan; 43(1):86-92. PubMed ID: 23151729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.